Cibus, Inc. (CBUS) vs Novogen Limited (KZIA)

Cibus, Inc. and Novogen Limited are both Biotechnology companies. Cibus, Inc. and Novogen Limited are of similar size ($114.6M and $111.8M). Novogen Limited has the higher net margin (0.00% vs −2,258.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Novogen Limited leads on 9 and Cibus, Inc. on 3.

Valuation

Metric CBUS KZIA Biotechnology median
P/E n/m n/m 7.88
P/S 27.02 n/m 11.47
P/B 7.93 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 1.46 0.74
EV/Sales 22.56 n/m 10.73
Earnings yield (107.84%) (2.27%) (28.84%)
Free cash flow yield (39.41%) 0.00% (23.03%)

Profitability

Metric CBUS KZIA Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (1,450.59%) — 0.00%
Net margin (2,258.89%) 0.00% 0.00%
Free cash flow margin (1,064.60%) 0.00% 0.00%
Return on equity (219.97%) 0.00% (57.72%)
Return on assets (29.77%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CBUS KZIA Biotechnology median
Revenue growth (TTM) (10.30%) — 5.64%
EPS growth (last fiscal year) 74.33% 63.24% —
Revenue growth, 5-year CAGR (31.34%) 11.56% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CBUS KZIA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.62 2.87 4.73
Net debt to EBITDA (0.28) 0.30 0.96

Dividend

Metric CBUS KZIA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CBUS KZIA Biotechnology median
Market cap 114.64m 111.79m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack